EXACT Sciences Announces Next Generation Stool-Based DNA Technology Study Results Of 92% For Colorectal Cancer Detection

�EXACT Sciences Corporation (NASDAQ: EXAS) proclaimed the published results of a study in which stool and blood plasm were assessed, in a head-to-head equivalence, for the detection of colorectal cancer (CRC). Using an improved BEAMing DNA detection technology from Johns Hopkins University, study results demonstrated 92 percent